GET DAILY SIGNALSBurning Rock Biotech (BNR): A +21% Path to the $15 Technical Level
Key Takeaways
- The $15 objective used in this analysis is drawn from public discussion and technical context, not a Wall Street analyst consensus, because Burning Rock Biotech Limited (BNR) lacks enough current, credible analyst price targets to form a meaningful average.
- At a latest verified close of $12.39, reaching $15 would require a gain of roughly 21%, a substantial move for a thinly traded small-cap.
- Analyst coverage is minimal: one firm (Jefferies) upgraded the stock to Hold in May 2026, but no dependable published price target was available from reputable sources, which is why the analyst method was not used.
- The strongest supporting factors are a high gross margin near 75%, improving cash-burn trends, and a cash balance that provides runway.
- The biggest risks are persistent net losses, declining revenue, a heavily loss-making profile, and China's healthcare pricing and regulatory environment.
- You can find more detail on the company's Major News, Today's Price Move, Forecast, and Earnings pages.
- To explore automated market analysis, browse Tickeron's Trending AI Robots.
How the $15 Benchmark Came Into View
Burning Rock Biotech Limited, a Guangzhou, China–based developer of next-generation sequencing (NGS) diagnostics for precision oncology, receives limited attention from Wall Street. Jefferies upgraded the ADR to Hold in May 2026, yet credible price targets from named analysts have not been consistently available from reputable sources. One aggregator shows a single "Sell" rating without a target, while others list Hold without a specific figure. As a result, the analyst-average approach cannot be applied responsibly. Instead, the $15 level reflects a technical recovery toward the shares' recent consolidation zone in the mid-$15s, where the stock traded as recently as early October 2026. It serves as a public-discussion and technical reference point rather than a consensus forecast.
Current Market Position and the Route to the Target
As of the latest verified close, BNR traded at $12.39, near the lower end of its 52-week range of $6.79 to $41.72. Reaching $15 implies a rise of about 21%, which represents a meaningful move for a company with a market capitalization near $130 million and average daily volume of only about 35,000 shares. The path would likely hinge less on valuation rerating and more on fundamental proof points: stabilizing revenue, a credible move toward breakeven, and evidence that its in-hospital and pharma research-and-development service lines can offset declines in legacy central-laboratory volumes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Factors That Could Support a Move Higher
Burning Rock's gross margin has remained strong near 75%, and recent commentary pointed to meaningful progress in narrowing losses and reducing cash burn. The company held roughly RMB 417 million in cash on its most recent balance sheet, providing a buffer while it transitions its revenue mix toward in-hospital testing and pharmaceutical research services. A constructive catalyst around its next earnings release, or an analyst upgrade accompanied by a first real price target, could reframe how the market values the stock and support a climb toward the $15 area.
Obstacles That Could Stand in the Way
The challenges are material. Burning Rock remains unprofitable, with a trailing-twelve-month net loss of roughly RMB 68 million and negative earnings per share (EPS), so it has no meaningful price-to-earnings (P/E) multiple to anchor a valuation. Revenue has declined on an annual basis, and its pharmaceutical research-services revenue can be lumpy. China's healthcare environment—including pricing pressure on diagnostics and regulatory uncertainty—adds risk, while thin trading volume can amplify volatility in both directions and make a sustained recovery harder to hold.
Technical Levels and Market Structure
The shares recently bounced from near $10 to a short-term high around $13.42, so that level acts as immediate resistance. Above it, the $15 zone—the fallback objective—represents the prior consolidation area. The far more distant 52-week high of $41.72 sits more than three times above the current price and reflects a period of much higher valuation; it should not be confused with a near-term target. On the downside, the 52-week low near $6.79 marks a longer-term support reference.
Time Horizon and Key Items to Watch
Because no named analyst has published a usable 12-month target, there is no consensus horizon to cite. Investors should treat any price objective for a stock this volatile as sensitive to near-term news. The most important upcoming items are the next earnings report and any guidance on revenue trajectory, cash burn, and the in-hospital and pharma-services mix, plus any new analyst initiations or rating changes. Macro factors such as interest-rate decisions and sentiment toward Chinese ADRs can also move the shares disproportionately given their low liquidity.
Exploring AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from evolving market conditions, technical behavior, and AI-driven analysis. For a low-liquidity name like BNR, these signals can help traders spot changes in trend and momentum more efficiently than manual chart review. Traders can use them to discover opportunities, track positions, and react to shifting conditions. Explore the signals to see how AI currently reads BNR's setup.
Personal Take on the Tickeron Platform
I have found Tickeron's AI tools particularly useful for scanning setups like BNR in real time. The platform's AI Daily Buy/Sell Signals and related analytics help me quickly gauge momentum shifts without spending hours on manual review. For low-volume names, this kind of systematic approach adds a layer of discipline to the process. It is worth testing the signals directly on the site to see how they align with your own analysis of the stock.
Final Assessment
Can BNR reach $15? The question hinges on a roughly 21% advance from $12.39, a substantial move for a thinly traded, still-unprofitable diagnostics company. The case for the move rests on a high gross margin, a large cash cushion, and progress in narrowing losses; the case against it rests on declining revenue, negative earnings, and Chinese healthcare and regulatory risks. With effectively no usable analyst price targets, the $15 figure is a technical recovery benchmark rather than a consensus, and it should be read as a scenario to monitor—not a forecast. The next earnings release, revenue guidance, and any fresh analyst coverage will be the clearest signposts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for BNR turns positive, indicating new upward trend
BNR saw its Momentum Indicator move above the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 71 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BNR just turned positive on November 06, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (67.298). P/E Ratio (-1.157) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties
Advertisement